AstraZeneca neurofibromatosis treatment gets orphan drug designation in Japan
30th Jun 2020 08:07
(Sharecast News) - AstraZeneca said on Tuesday that selumetinib, its treatment for genetic disease neurofibromatosis type 1, has been granted orphan drug designation in Japan.
Read moreSingle course of Covid-19 treatment to cost $2,340 per patient - Gilead
29th Jun 2020 12:00
(Sharecast News) - Gilead Sciences has announced it will charge developed countries $390 a vial for remdesivir, its antiviral drug currently being investigated for use in Covid-19 patients.
Read moreAntibody levels of Covid-19 patients decline quickly, small study shows
22nd Jun 2020 12:54
(Sharecast News) - Levels of antibodies in people who have suffered Covid-19 reportedly falls sharply in the two to three months following their infection, a study showed, although the implications for patient immunity were unclear.
Read moreFriday broker round-up
19th Jun 2020 14:21
(Sharecast News) - Domino's Pizza Group: Berenberg downgrades to sell with a target price of 250p.
Read moreBerlin invests 300.0m euro in Covid-19 maker CureVac
15th Jun 2020 12:07
(Sharecast News) - Berlin unveiled a multi-million dollar investment into German biotechnology outfit CureVac, alongside dievini Hopp BioTech, SAP co-founder Dietmar Hopp's holding company.
Read moreAstraZeneca to provide Europe with 400m doses of Covid-19 vaccine, if successful
15th Jun 2020 07:05
(Sharecast News) - AstraZeneca inked a deal with for European countries to provide its Covid-19 vaccine, if successful, starting from the end of 2020.
Read moreUS to start studies into three vaccine candidates from July
10th Jun 2020 14:58
(Sharecast News) - Authorities in the US are planning to fund and conduct studies into three experimental vaccines for the novel coronavirus, including that being developed by Oxford University's Jenner institute and AstraZeneca.
Read moreAstraZeneca approached Gilead about merger - report
8th Jun 2020 07:33
(Sharecast News) - AstraZeneca has approached Gilead Sciences of the US about a potential merger to create a $240bn drugmaker, according to a report.
Read moreSunday newspaper round-up: Pandemic, Jobs, AstraZeneca
7th Jun 2020 12:21
(Sharecast News) - Fresh evidence of China's shocking cover-up of the pandemic outbreak has been found in censored media reports from Wuhan. Samples taken from sick patients and analysed by at least five laboratories had confirmed the existence of a lethal new coronavirus before China told global health authorities about an infectious disease that it claimed was unidentified. - Mail on Sunday
Read moreAstraZeneca strikes deals for more Covid-19 vaccine doses
5th Jun 2020 11:56
(Sharecast News) - AstraZeneca has signed deals to produce more than 1bn extra doses of Oxford University's Covid-19 vaccine including with two organisations backed by Bill and Melinda Gates.
Read moreMonday broker round-up
1st Jun 2020 13:47
(Sharecast News) - Johnson Matthey: Liberum downgrades to hold with a target price of 2,100p.
Read moreAstraZeneca clears regulatory hurdles with 'Brilinta' and 'Lynparza'
1st Jun 2020 07:37
(Sharecast News) - AstraZeneca announced on Monday that 'Brilinta', or ticagrelor, has been approved in the United States to reduce the risk of a first heart attack or stroke in high-risk patients with coronary artery disease (CAD) - the most common type of heart disease.
Read moreAstraZeneca upbeat on latest 'Tagrisso' trial results
29th May 2020 07:34
(Sharecast News) - AstraZeneca said on Friday that detailed results from the phase 3 'ADAURA' trial showed that 'Tagrisso', or osimertinib, demonstrated a "statistically significant and clinically meaningful improvement" in disease-free survival in the adjuvant treatment of patients with early-stage epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC), after complete tumour resection with curative intent.
Read moreInitial results of study into Oxford's Covid-19 vaccine imminent, AstraZeneca chief says
28th May 2020 18:19
(Sharecast News) - Some members of the Oxford University research team trying to develop a vaccine against the novel corona virus are already privy to initial results for early-stage human trials and their publication is imminent, AstraZeneca's chief said.
Read moreMerck to pursue Covid-19 vaccine using same approach as against Ebola
26th May 2020 12:33
(Sharecast News) - US pharmaceutical giant Merck has penned an agreement with researchers at IAVI to develop a vaccine candidate against the novel coronavirus which provokes Covid-19 using the same underlying technology as the ERVEBO vaccine for the Ebola virus.
Read more